BioStock: Xintela presents the plans for 2022 in its Q4 report

Xintela recently published its fourth quarter report, which describes the company’s plans for 2022. During the year, the stem cell product XSTEM will enter clinical trial for the first time in humans in two different phase I/IIa clinical studies; one in knee osteoarthritis and one in difficult-to-heal leg ulcers, the latter of which will be partly financed by a grant of 4.8 MSEK from Vinnova.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/xintela-presents-the-plans-for-2022-in-its-q4-report/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se